Hyperhomocysteinaemia is not related to risk of distal somatic polyneuropathy: The Hoorn Study

Journal of Internal Medicine

Volumn 246, Issue 6, 1999, Pages 561-566

  Hoogeveen, Ellen K ^a   Kostense, P J ^a,b   Valk, G D ^a   Bertelsmann, F W ^c   Jakobs, C ^c   Dekker, J M ^a   Nijpels, G ^a   Heine, R J ^a,c   Bouter, L M ^a,b   Stehouwer, C D A ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Homocysteine; Polyneuropathy; Pyridoxine

Indexed keywords

ARTICLE; CORONARY RISK; GLUCOSE TOLERANCE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYNEUROPATHY; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; COMORBIDITY; DIABETIC NEUROPATHIES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK ASSESSMENT;

EID: 0033406333     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00566.x     Document Type: Article

References (30)

1. 1 Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabetic Med 1998; 15: 97-112.
2. 2 Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabetic Med 1998; 15: 508-14.
3. 3 Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-4.
4. 4 Maser RE, Steenkiste AR, Dorman JS et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456-61.
5. 5 Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
6. 6 Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD. Sural nerve oxygen tension in diabetes. BMJ 1988; 293: 1053-4.
7. 7 Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994; 10: 189-224.
8. 8 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
9. 9 Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998; 49: 31-62.
10. 10 Hoogeveen EK, Kostense PJ, Beks PJ et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
11. 11 Hoogeveen EK, Kostense PJ, Jager A et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study. Kidney Int 1998; 54: 203-9.
12. 12 Stehouwer CDA, Nauta JJP, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
13. 13 Welch GN, Loscalzo J. Mechanisms of disease: homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
14. 14 Beks PJ, Mackaay AJC, de Neeling JND, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: The Hoorn Study. Diabetologia 1995; 38: 86-96.
15. 15 World Health Organisation Study Group on Diabetes Mellitus. Technical Report Series No 727. Geneva: WHO. 1985.
16. 16 de Neeling JND, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Sensory thresholds in older adults: reproducibility and reference values. Muscle Nerve 1994; 17: 454-61.
17. 17 Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-79.
18. 18 Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-6.
19. 19 Grootenhuis PA, Westenbrink S, Sie CMTL, de Neeling JND, Kok FJ, Bouter LM. A semi-quantitative food frequency questionnaire for use in epidemiologic research among the elderly: Validation by comparison with dietary history. J Clin Epidemiol 1995; 48: 859-68.
20. 20 Burke BS. The dietary history as a tool in research. J Am Diet Assoc 1947: 23: 1041-6.
21. 21 Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
22. 22 Bernstein AL. Vitamin B6 in clinical neurology. Ann NY Acad Sci 1990; 585: 250-60.
23. 23 Sosenko JM, Boulton AJM, Gardia MT, Ward JD, Skyler J. The association between symptomatic sensory neuropathy and body stature in diabetic patients. Diabetes Res Clin Pract 1988; 4: 95-8.
24. 24 Hofmann MA, Kohl B, Zumbach MS et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998; 21: 841-8.
25. 25 Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993; 103: 149-57.
26. 26 Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnson K, Feldt-Rasmussen B, Jensen T. Microalbuminuria: Implications for micro-and macrovascular disease. Diabetes Care 1992; 15: 1181-91.
27. 27 Valk GD, de Sonnaville JJJ, van Houtum WH et al. The assessment of diabetic polyneuropathy in daily clinical practice. Muscle Nerve 1997; 20: 116-8.
28. 28 Valk GD, Nauta JJP, Strijers RLM, Bertelsmann FW. Clinical examination versus neurophysiological examination in the diagnosis of diabetic polyneuropathy. Diabetic Med 1992; 9: 716-21.
29. 29 Schaumburg H, Kaplan J, Windebank A et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med 1983; 309: 445-8.
30. 30 Collier J. Vitamin B-6: food or medicine? BMJ 1998; 317: 92-3.